New model aims to prevent kidney failure in brain cancer therapy
NCT ID NCT07406230
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 50 adults with primary central nervous system lymphoma who are receiving high-dose methotrexate, a key chemotherapy. The goal is to see if measuring the drug early in the blood can predict later kidney problems. By identifying at-risk patients sooner, doctors could take steps to prevent serious side effects and keep treatment on track.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique - Hôpitaux de Marseille
Marseille, 13005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune booster outsmart brain lymphoma?
- Can a daily pill keep brain lymphoma at bay after remission?
- Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?
- New antibody combo aims to treat brain lymphoma
- Could a cancer drug shrink recurrent brain tumors?
- New cocktail aims to shrink brain tumors